January 28, 2026 Release Highlights Copied
Practice Insights is pleased to announce updates in the application to support the Merit-Based Incentive Payment System (MIPS) and Enhancing Oncology Model (EOM).
MIPS Quality Measures Dashboard
The MIPS Quality Measures Dashboard will be updated to reflect the following refinement(s):
| Measure | Update | Practice Impact |
| MIPS 144: Pain Care Plan | Technical fix implemented to ensure patients who received only oral chemotherapy are not assessed for denominator credit. | Practices will notice a shift in the Denominator and/or Numerator. |
| PIMSH 4: Patient Reported Pain Improvement | Technical fix implemented to ensure new episodes do not begin after December 1st; there is not enough time allotted for the provider to assess improvement. Previously, denominator credit was attributed without allowing ample time for the provider to meet the numerator. | Practices will notice a shift in the Denominator, Denominator Exclusion, and Numerator. |
MIPS Promoting Interoperability Dashboard
The MIPS Promoting Interoperability Dashboard will be updated to reflect the following refinement(s):
| Measure | Update | Practice Impact |
| Location Filter | Technical fix to re-enable location filter for dashboard | Practices will see the correct numerator/denominator/performance when using the location filter. |
EOM Performance Measure Dashboard
The EOM Performance Measures Dashboard will be updated to reflect the following refinement(s):
| Measure | Update | Practice Impact |
| EOM-4B: Pain Care Plan | Technical fix implemented to ensure patients who received only oral chemotherapy are not assessed for denominator credit. EOM-4B will now display the same performance data as MIPS 144. | Practices will notice a shift in the Denominator and Numerator. |
Status of Dashboard Updates for 2026
CMS releases updates to the quality measure specifications annually for the MIPS program. These measure specifications have been reviewed, and Practice Insights is working on the required technical updates to align with the revised requirements. Ontada will continue to notify practices once measures have been updated based on the current 2025 requirements.
Please note that this list reflects updates for 2025. Revisions to the 2026 measures are currently pending.
| Measure Number | Description |
| MIPS Quality Measures Dashboard | |
| MIPS #001 | Diabetes Hemoglobin A1c (HbA1cc) Poor Control (>9%) (Inverse Measure) |
| MIPS #047 | Advance Care Plan |
| MIPS #130 | Current Medications Documentation |
| MIPS #134 eCQM | Preventive Care Screening: Screening for Depression and Follow Up Plan |
| MIPS #134 CQM/Registry | Preventive Care Screening: Screening for Depression and Follow Up Plan |
| MIPS #143 | Pain Intensity Quantified |
| MIPS #144 | Pain Care Plan |
| MIPS #226 | Tobacco Screening and Cessation |
| MIPS #236 | Controlling High Blood Pressure |
| MIPS #238 | Use of High-Risk Medications in Older Adults (Inverse Measure) |
| MIPS #374 | Closing the Referral Loop |
| MIPS #450 | Appropriate Treatment for Patients with Stage I (T1c) III Her2 Positive Breast Cancer |
| MIPS #451 | RAS (KRAS & NRAS) Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-EGFR Monoclonal Antibody Therapy |
| MIPS #453 | Proportion Receiving Chemotherapy in the Last 14 Days of Life (Inverse Measure) |
| MIPS #457 | Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3 Days |
| MIPS #462 | Bone Density Evaluation for Patients with Prostate Cancer and Receiving Androgen Deprivation Therapy |
| MIPS #487 | Screening for Social Drivers of Health |
| PIMSH #1 | Advance Care Planning in Metastatic Disease |
| PIMSH #4 | Patient-Reported Pain Improvement |
| PIMSH #9 | Supportive Care Drug Utilization in the Last 14 Days of Life (Inverse Measure) |
| PIMSH #10 | Hepatitis B Serology Testing and Prophylactic Treatment Prior to Receiving Anti-CD20 Targeting Drugs |
| PIMSH #13 | Proportion of Stage IV nsNSCLC Patients Tested for Actionable Biomarkers and Received Mutation-Targeted Therapy |
| PIMSH #15 | Antiemetic Therapy for Low-and Minimal-Emetic-Risk Antineoplastic Agents in the Infusion Center-Avoidance of Overuse (Inverse Measure) |
| PIMSH #16 | Appropriate Antiemetic Therapy for High-and Moderate-Emetic-Risk Antineoplastic Agents in the Infusion Center |
| PIMSH #17 | Utilization of Prophylactic GCSF for Cancer Patients Receiving Low-Risk Chemotherapy (Inverse Measure) |
| PIMSH #18 | Resolution or Improvement of a Health-Related Social Need |
| EOM Performance Measures Dashboard | |
| EOM-4A | Pain Intensity Quantified |
| EOM-4B | Pain Care Plan |
| EOM-5 | Preventive Care Screening: Screening for Depression and Follow Up Plan |